Leukemia
CPX-351 Versus 7+3 for Older Patients (2651)
Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75Yyears of Age with Untreated High Risk (secondary) AML
Investigator: John Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01696084
Intensified Methotrexate, Nelarabine (Compound 506U78 IND # 52611) and Augmented BFM Therapy in Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia
Investigator: Blythe Thomson, MD; Conditions: Acute Lymphoid Leukemia (ALL); Status: Recruiting; Study ID: NCT00408005
A Phase 1, Dose Escalation Study of Plerixafor in combination with Cytarabine and Daunorubicin in Patients with De Novo Acute Myeloid Leukemia
Investigator: Pamela Becker, MD, PhD; Conditions: De Novo Acute Myeloid Leukemia (AML); Status: Closed; Study ID: NCT00990054
Safety and Clinical Activity of TreandaTM (Bendamustine HCL) and Idarubicin in Combination Therapy for Patients Over Age 60 with Previously Untreated Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (MDS)
Investigator: John M. Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia; Status: Closed; Study ID: NCT01141725
A Phase I, Open-Label, Dose-Escalation Study to Evaluate The Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (AML).
Investigator: Bart Scott, MD; Conditions: Myelodysplastic Syndromes (MDS);, Chronic Myelomonocytic Leukemia (CMML);, Acute Myelogenous Leukemia (AML); Status: Closed; Study ID: NCT00528983
A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small LymphoCtic Lymphoma (SLL)
Investigator: John Pagel, MD, PhD; Conditions: Leukemia, Lymphoma; Status: Recruiting; Study ID: NCT00918723
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics, And Pharmacodynamics Of PF 04449913, An Oral Hedgehog Inhibitor, Administered As Single Agent In Select Hematologic Malignancies
Investigator: Vivian Oehler, M.D,; Conditions: Hematologic Malignancies; Status: Closed; Study ID: NCT00953758
Idarubicin, Cytarabine and Pravastatin (IAP) for Induction of Newly Diagnosed Acute Myeloid Leukemia (AML)
Investigator: Raya Mawad; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01831232
A Phase II Study of Tosedostat in Combination With Either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS
Investigator: John M. Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01567059
A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Investigator: Vivian Oehler, MD; Conditions: Chronic Myeloid Leukemia; Status: Recruiting; Study ID: NCT01650805
A Phase 3, Multicenter, Randomized Study to Evaluate the Substitution of Marqibo® (Vincristine Sulfate Liposomes Injection, VSLI) for Standard Vincristine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects = 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Investigator: Andrei Shustov, MD; Conditions: Acute Lymphoid Leukemia; Status: Recruiting; Study ID: NCT01439347
A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia
Investigator: John Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia (AML); Status: Recruiting; Study ID: NCT01756677
An Open-Label, Multicenter, Phase Ib Trial of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Investigator: Ajay K. Gopal, MD; Conditions: Chronic Lymphocytic Leukemia; Status: Closed; Study ID: NCT01300247
COG - Standard Risk B-Precursor Acute Lymphoblastic Leukemia: A Phase III Group Wide Study
Investigator: Blythe Thomson, MD; Conditions: Acute Lymphoid Leukemia (ALL); Status: Closed; Study ID: NCT00103285
Randomized Phase II Study Comparing Two Administration Schedules of Flavopiridol (Alvocidib, NSC 649890, IND 46,211) Given in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias (AML)
Investigator: John Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia (AML); Status: Closed; Study ID: NCT00795002
Clofarabine in Combination with Cytarabine (Ara-C) and G-CSF Priming Followed by Infusion of Ex Vivo Expanded Cord Blood Progenitors for Patients with AML
Investigator: Colleen Delaney, MD, MSc; Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia; Status: Closed; Study ID: NCT01031368
Feasibility of Outpatient Induction Chemotherapy for Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
Investigator: Pamela S. Becker, MD, PhD; Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome; Status: Recruiting; Study ID: NCT01807091
Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality
Investigator: Roland B. Walter, MD; Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome; Status: Recruiting; Study ID: NCT01804101
Join Us On